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Abstract Patient-reported outcomes (PROs) are an
important means of evaluating the treatment benefit of
new medical products. It is recognized that PRO mea-
sures should be used when assessing concepts best
known by the patient or best measured from the patient’s
perspective. As a result, there is growing emphasis on
well defined and reliable PRO measures. In addition,
advances in technology have significantly increased
electronic PRO (ePRO) data collection capabilities and
options in clinical trials. The movement from paper-
based to ePRO data capture has enhanced the integrity
and accuracy of clinical trial data and is encouraged by
regulators. A primary distinction in the types of ePRO
platforms is between telephone-based interactive voice
response systems and screen-based systems. Handheld
touchscreen-based devices have become the mainstay for
remote (i.e., off-site, unsupervised) PRO data collection
in clinical trials. The conventional approach is to provide
study subjects with a handheld device with a device-
based proprietary software program. However, an
emerging alternative for clinical trials is called bring
your own device (BYOD). Leveraging study subjects’
own Internet-enabled mobile devices for remote PRO
data collection (via a downloadable app or a Web-based
data collection portal) has become possible due to the
widespread use of personal smartphones and tablets.
However, there are a number of scientific and opera-
tional issues that must be addressed before BYOD can be
routinely considered as a practical alternative to con-
ventional ePRO data collection methods. Nevertheless,
the future for ePRO data collection is bright and the
promise of BYOD opens a new chapter in its evolution.
Key Points for Decision Makers
Patient-reported outcome (PRO) endpoints are often
necessary to adequately evaluate the treatment
benefit provided by new medical products (e.g.,
drugs) in clinical trials.
The movement from paper-based to electronic PRO
(ePRO) data collection has enhanced the integrity
and accuracy of PRO data in clinical trials.
The US Food and Drug Administration has made it
clear that electronic capture of clinical trial source
data is preferred over paper-based data collection.
The bring your own device (BYOD) approach to
ePRO data collection in clinical trials has
considerable promise, but a number of questions
need to be answered prior to its routine adoption.
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In the evaluation of new medical products, regulatory
agencies (e.g., the US Food and Drug Administration
[FDA]) rely on clinical trial endpoints that are believed to
adequately assess the treatment benefit provided by the
product. Treatment benefit is demonstrated by evidence
that the treatment has a positive impact on how long a
patient lives or how a patient feels or functions in daily life
[1]. The regulatory uses for documented treatment benefit
are marketing approval and label claims [2]. A claim of
treatment benefit must be supported by substantial evi-
dence from adequate and well controlled studies using well
defined and reliable assessments [3].
Studies to assess treatment benefit are usually compar-
ative efficacy trials, but can be comparative safety trials
(e.g., assessing relative levels of a specific treatment-rela-
ted toxicity). Along with biomarkers (e.g., HbA1C, blood
pressure) and survival, clinical outcome assessments
(COAs) can be used as primary or secondary endpoints in
trials to determine whether a drug provides a treatment
benefit. COAs include patient-reported outcomes (PROs),
clinician-reported outcomes, observer-reported outcomes,
and performance outcomes [4]. The focus of this article is
the assessment of PRO endpoints in clinical trials.
A PRO instrument collects treatment benefit data
directly from patients, without interpretation by clinicians
or others [5]. As recognized by the FDA in its Guidance for
Industry titled Patient-Reported Outcome Measures: Use
in Medical Product Development to Support Labeling
Claims (aka ‘PRO Guidance’), PRO instruments should be
used when measuring concepts best known by the patient
or best measured from the patient’s perspective [5]. The
purpose of this article is to describe electronic PRO (ePRO)
data collection in clinical trials assessing the efficacy of
new medical products for regulatory approval and to pro-
vide a brief overview of the current technology and
emerging trends.
2 The Shift Toward ePRO Data Collection
Based on the evidence that has been mounting over the past
25 years, unsupervised paper-based self-reports of function
and symptom experience are far from optimal compared
with data collected electronically [6–8]. For example,
Stone and colleagues demonstrated that, although study
subjects reported high compliance (i.e., daily data entry at
required times) with a paper diary, their actual compliance
(i.e., actual completion times in relation to when diaries
should have been completed) was very low when compared
with actual compliance of subjects using an electronic
diary [7]. As stated by Ganser and colleagues [9, p. 49],
paper-based approaches to patient-reported data collection
can ‘‘result in untimely, unreadable, missing, illogical or
otherwise faulty data.’’ Hence, a number of scientific,
regulatory, and practical considerations are driving the shift
to electronic capture of PRO endpoints in clinical trials.
The emergence of ePRO technologies has been a pro-
foundly significant innovation for PRO endpoint assess-
ment; it has significantly increased data collection
capabilities and options in clinical trials.
ePRO systems can lead to more accurate and complete
data [7, 9], improved protocol compliance [10], avoidance
of secondary data entry errors [9], easier implementation of
skip patterns [11], less administrative burden [10, 12], high
respondent acceptance [12–14], reduced sample size
requirements [9], and potential cost savings [15, 16].
Compliance with self-reported data entry requirements
specified by the protocol in a clinical trial can be improved
through the use of alarms and reminders in addition to
more timely follow-up with non-compliant subjects that is
enabled by nearly real-time investigator data monitoring
capabilities [17]. However, it must be stated that the many
advantages of ePRO data capture may not materialize if
study subjects do not receive adequate training on the
ePRO device/system and the data entry requirements of the
study protocol.
The accelerating movement from paper diaries and
questionnaires to ePRO data collection systems has
enhanced the integrity and accuracy of data collected in
clinical trials [9]. This transition, along with FDA’s release
of the PRO Guidance, has elevated the science of PRO
measurement. Among the regulatory bodies of the world,
the FDA has taken a leadership role in advancing sound
COA endpoint assessment. For example, the following
quote from the PRO Guidance explicitly endorses the
functionality of electronic data collection platforms and,
hence, implicitly endorses the shift to ePRO: ‘‘If a patient
diary or some other form of unsupervised data entry is
used, we plan to review the clinical trial protocol to
determine what steps are taken to ensure that patients make
entries according to the clinical trial design and not, for
example, just before a clinic visit when their reports will be
collected’’ [5, p 9].
Electronic data collection provides a record of the date
and time entries are made and can impose specified time
windows for data entry [18]. This functionality can help
prevent (or identify) back-filling or forward-filling of
entries that can undermine the quality and accuracy of
paper-based diaries or questionnaires [7]. In addition,
ePRO systems can decrease missing or unusable data by
compelling a response and by not allowing entry of out-of-
range, contradictory, or extraneous responses. The FDA
Guidance for Industry titled Electronic Source Data in
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Clinical Investigations provides further support for the
electronic capture of PRO endpoints in clinical trials [19].
3 Ensuring High-Quality Measurement
The advantages of electronic data capture are well docu-
mented, but those advantages mean little if measurement
error is introduced by poor implementation of a PRO
instrument on an ePRO platform. This is a particularly
important consideration when, as is often the case, the PRO
instrument being used was initially developed as a paper-
based questionnaire. The migration of paper-based instru-
ments to electronic data collection modes must be properly
planned and executed so that respondents interpret and
respond to the PRO instrument’s items the same way
regardless of the data collection mode. To address this
issue, the International Society of Pharmacoeconomics and
Outcomes Research (ISPOR) released a task force report in
2009 that provided recommendations as to the type and
amount of evidence needed to support measurement
equivalence between electronic and paper-based PRO
measures [20]. Subsequently, another ISPOR task force
report expanded those recommendations to situations
where more than one mode of PRO data collection is being
considered for a clinical trial [21]. This task force recog-
nized that sufficient evidence may be available in the future
to support the assumption of measurement equivalence
across PRO data collection modes in most circumstances
where a faithful migration has occurred [21], since a
growing body of empirical research shows that, as long as
substantive content changes are not made, paper and
electronic versions of PRO instruments generally provide
comparable data [22].
In addition, the ePRO Consortium, which has ten ePRO
system providers as members, undertook the development
of best practice recommendations to facilitate the suc-
cessful implementation of ePRO data capture. The ePRO
Consortium (http://c-path.org/programs/epro) was estab-
lished in 2011 by the non-profit Critical Path Institute to
collaboratively address scientific, not commercial, issues
related to the electronic capture of PRO endpoints in
clinical trials. The best practice documents (http://c-path.
org/programs/epro/#section-5648) completed by the ePRO
Consortium and available through its Web page include
Best Practices for Migrating Existing Patient-Reported
Outcome Instruments to a New Data Collection Mode, Best
Practices for Electronic Implementation of Patient-
Reported Outcome Response Scale Options, and Best
Practices for Maximizing Electronic Data Capture Options
during the Development of New Patient-Reported Outcome
Instruments. The latter document addresses the importance
of considering all possible data collection modes when
developing new instruments. Too many PRO instrument
developers are paper-centric and fail to contemplate alter-
native data collection modes when developing their items
and selecting response scales. For example, a true visual
analog scale (VAS) has descriptive verbal anchors at each
end with an uninterrupted line in between. On a self-
administered paper-based questionnaire, the respondent
can be asked to place a mark or ‘X’ at the point on the line
that best reflects his or her response; however, for a tele-
phone-administered version of the same questionnaire,
there is no way to operationalize the VAS response options
without converting it to a numeric rating scale.
Another consideration that can undermine high-quality
measurement in clinical trials that transcends individual
instrument issues is the development and deployment of
the overall ePRO system; this is far from a trivial task.
ISPOR’s ePRO Systems Validation Task Force developed
recommendations for clinical trial teams regarding the
validation of electronic systems used to collect PRO data in
clinical trials [23]. The task force’s primary goal was to
bring attention to the technical nature of ePRO systems and
the essential steps in the ePRO system validation process. It
is quite clear that ePRO system validation requires col-
laboration between the ePRO system provider and the
clinical trial team, since both parties have a substantive and
complementary role to play in the ePRO system validation
process.
4 ePRO Data Collection Technologies
The availability of new data capture technologies has
enabled clinical trial protocols to be designed in ways that
allow for more timely and patient-friendly approaches to
PRO endpoint assessment [21, 24]. The selection of an
ePRO data collection technology should never be an
afterthought in a drug development program. There are a
number of factors that must be considered when selecting
the most appropriate mode of data collection, including
patient population, location of data collection, character-
istics of the instrument, data collection schedule, feasibil-
ity, and cost. Eremenco and colleagues [21] provide an
overview of these factors. Selecting the most appropriate
approach to ePRO data collection is essential to the success
of the clinical trial.
In clinical research, PRO data collection can occur at a
study site (e.g., clinic) or off-site in an unsupervised setting
(e.g., subject’s home, workplace, or school). To enable
more timely and accurate self-reporting and to avoid
potential recall bias, off-site assessment of symptom or
functional endpoints is often optimal. For either study site
or off-site (i.e., remote) PRO data collection, ePRO plat-
forms are recommended over paper-based approaches, but
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it is especially critical for unsupervised, remote data entry
due to the reasons discussed above.
A primary distinction in the types of ePRO platforms is
between telephone-based interactive voice response (IVR)
systems and screen-based systems. Within the screen-based
approaches are device-based systems (i.e., proprietary
software installed on a specific hardware platform), Web-
based systems, and downloadable application (app)-based
systems that utilize the subject’s or site’s screen-based
device. The different types of available ePRO data col-
lection technologies are described briefly below; further
description of these technologies is provided by Eremenco
and colleagues [21]. Since using downloadable apps for
collecting PRO data in clinical trials is an emerging
methodology, this topic is only mentioned briefly in the
descriptions below, but will be covered in more depth in
the context of bring your own device (BYOD) trials later in
this article.
4.1 Interactive Voice Response Systems
IVR systems leverage landlines or cellular telephones
already available to subjects; hence, no hardware deploy-
ment is required and minimal subject training is necessary.
IVR systems use a pre-recorded question and response
option script and subjects respond via the phone’s keypad.
Data are stored directly to a central database. IVR systems
can be implemented to call the subject or to allow the
subject to call the system at scheduled data collection time
points.
4.2 Handheld Devices
Although self-reported clinical trial data had been col-
lected via computerized systems previously, the adop-
tion of personal digital assistants (PDAs) in the late
1980s and early 1990s truly changed the PRO landscape
and accelerated the movement to ePRO data capture [11,
25]. Initially, these devices used offline synchronization
and required temporary data storage on the device until
the data could be uploaded to a local (e.g., site-based)
computer or central server [17]. Advances involving the
integration of wireless and cellular phone capabilities
expanded their utility exponentially since they allowed
data to be transferred immediately from the device to a
central server/database. Hence, most of these handheld
devices are now mobile telephones (e.g., smartphones)
and they have become the mainstay of ePRO data col-
lection. Their portability and touch screen functionality
provide a significant advantage over other data collec-
tion modes, particularly for clinical trials requiring fre-
quent remote PRO data capture (e.g., symptom or event-
based diaries).
Although most handheld devices used in clinical trials
are device-based systems, handhelds can also provide
access to Web-based data collection portals (e.g., interac-
tive Web response system) or provide ePRO functionality
through a downloadable app. However, it must be noted
that using a handheld device to access a website for clinical
trial data collection assumes that functionality and ren-
dering of the PRO instrument’s items on the device’s
screen are optimized for that particular operating system,
browser, and screen size [17].
4.3 Tablet Computers
Tablet computers represent another relatively mobile,
touch screen-enabled data collection platform. Although
the size differences are narrowing, tablets are generally
larger than traditional handheld devices and smaller than
laptop computers. The larger screen size of a tablet com-
pared with a handheld, and the relative mobility and ease of
use compared with a laptop, make tablets the primary
platform for site-based ePRO data collection. As with
handheld devices, tablets can be device-based systems,
provide access to Web-based portals, or be used with
downloadable ePRO apps.
4.4 Desktop or Laptop Computers
Although no longer used as often in clinical trials for data
entry by patients, desktop and laptop computers remain
platforms for collecting PRO data. They generally have
larger screens but usually lack touch screen functionality;
subjects use a keyboard and/or mouse to enter responses.
Handheld devices and tablets have become the predomi-
nant ePRO platforms, but desktop and laptop computers are
still used to capture site-based PRO data as well as remo-
tely captured data. The larger screen size of a desktop or
laptop can be an advantage in certain patient populations or
in situations where a larger representation of a PRO
instrument or its items/components would be preferable.
As with the other Internet-enabled screen-based platforms,
desktop and laptop computers can be device-based sys-
tems, provide access to Web-based portals, or be used with
downloadable ePRO apps.
4.5 Digital Pen
An ePRO platform that doesn’t fit into either a screen-
based or telephone-based system category is the digital
pen. Although digital pens are not used to collect a sig-
nificant share of ePRO data in clinical trials, they are
available. With digital pen technology, study subjects write
their responses on a paper questionnaire that has been
specially printed to enable the pen to locate its position on
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the questionnaire and record what is being written. Along
with a ballpoint ink cartridge, digital pens contain a pres-
sure sensor, a camera to capture the written data, a
microprocessor, memory, and a battery. Some digital pens
have a Bluetooth transceiver that enables the responses
captured by the pen’s camera to be uploaded to a Web-
based server in real time. Other pens use a docking cradle
attached to a computer that uploads the data to the server
via the Internet.
5 The Emergence of Bring Your Own Device (BYOD)
As mentioned above, handheld devices have become the
mainstay for remote (i.e., off-site, unsupervised) ePRO data
collection in clinical trials. The conventional approach has
been to provide to study subjects (via the study sites) a
handheld device with a device-based proprietary software
program (i.e., a stand-alone device). This approach has
worked well in ensuring subjects have a dedicated, ‘locked
down’ device on which they can enter study data in a
controlled manner; however, as described by Yeomans
[17], there are a number of important considerations with
this approach, including the following: provisioning costs
(i.e., costs associated with the purchase or lease of the
devices used in the trial); supply issues (i.e., delivering the
devices to the study sites for distribution to the subjects and
collection of the devices at study completion); training of
the site staff so that they can train subjects on the handling
and use of the device; maintenance (i.e., replacement of
faulty devices); and maintaining a help desk for device-
related questions from sites or subjects.
Hence, this can be costly for sponsors, challenging for
study sites, and inconvenient for study subjects, who may
already carry a separate handheld device for personal use.
Due to the widespread use of personal smartphones,
leveraging study subjects’ own mobile device for remote
PRO data collection is an attractive alternative for clinical
trials. One way this can be accomplished is by having study
subjects access Web-based data collection portals from
their own Internet-enabled mobile device. Yeomans [17]
briefly introduces three examples of efficacy trials for
drugs or devices that incorporated this type of Web-based
PRO data collection. The other option involves having the
subject download a software app to their own mobile
device. The subject runs the app locally on the device and
completes the PRO instrument. The data are then trans-
mitted via the Internet (Wi-Fi) or cellular signal. We know
of no publicly available information on clinical trials that
have used an app to collect primary or secondary PRO-
based efficacy data. However, there is increasing interest in
developing PRO data collection apps and, as a result, it is
imperative that both the potential benefits and challenges
be delineated and seriously considered. Although this
approach has many strengths and addresses some short-
comings of current approaches, there are also scientific and
operational questions that must be addressed.
6 Potential Benefits and Challenges of BYOD
In the field of medical research, BYOD, in its broadest def-
inition, means allowing participants in a clinical trial to use
their own computer devices (e.g., smartphone, tablet, laptop,
desktop PC) to access and respond to study-related PRO
questionnaires. As discussed, this is a departure from tradi-
tional studies utilizing ePRO where patients are provided
with the hardware they need to enter study data, typically a
tablet or desktop computer for site-based questionnaires and
a PDA or smartphone for remote questionnaire completion.
There are a number of factors that make BYOD a compelling
model for clinical trials (Box 1); however, there are key
outstanding issues that need to be adequately addressed
before BYOD becomes a viable model for clinical trials.
Although the technology is available to do it today, enthu-
siasm for doing it should not trump the need to approach it in
a measured and thoughtful manner.
6.1 Downloading Software to Devices
One of the key issues standing in the way of widespread
adoption of BYOD in clinical trials is how one gives the
Box 1. Examples of Perceived Advantages of the BYOD Approach in Clinical Trials
Reduced costs for clinical trial sponsors as study speciﬁc hardware does not need to be 
provided and distributed
Reduced burden on clinical trial subjects as they can use the hardware they are most 
familiar with and have access to in their normal day to day lives
Reduced burden on clinical trial study sites as they do not need to manage devices
Streamlined process for giving access to data collecon enables paent-centric studies 
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study subject access to the PRO instruments they are
required to complete during the study. With Web-enabled
devices such as smartphones, subjects could access the
instruments on their Web browser. However, this approach
requires active Internet access in order to view the PRO
instruments and enter data. The process of entering data on
a mobile device via the Internet can vary based on the
subject’s network connection; subjects using their mobile
device to enter data on a website may have to wait for the
browser screens to load and respond. In addition, not all
browsers are created equally and functionality can vary
between different browsers, and between different versions
of the same browser. Security is a heightened concern
when transmitting data over an open Internet connection.
An alternative to entering data on a website is the use of
apps, where the subject downloads a small piece of soft-
ware onto their smartphone that would display the PRO
instruments(s) in a relatively consistent manner across
handsets, barring differences in screen size. This has the
important advantage of allowing subjects to respond to
questionnaires and provide PRO data when they do not
have Internet access. While native apps can address some
of the issues above, they present unique considerations.
New functionality for a Web browser can be built and
deployed quickly; a native app will take longer, since it
must go through an entire software development lifecycle.
However with both of these approaches, Web and app,
there can be an issue with ensuring the wide range of
devices, operating systems, and Web browsers available
are compatible with any app and Web system that is
developed. This can be overcome by creating the app and
Web system on the widely used operating systems such as
Android and iOS, and the widely used Web browsers such
as Internet Explorer, Firefox, Safari, and Chrome, to ensure
greater access and compatibility. However, this does risk
creating issues in countries and populations where other
operating systems and browsers are more predominant.
6.2 Equivalence Across Data Collection Modes
Another key issue is that of equivalence of PRO instruments
across different data collection platforms or modes, partic-
ularly when they are being used to support primary or key
secondary endpoints. The FDA expects the sponsor to
demonstrate that a PRO instrument that has been ‘modified’
is capturing equivalent data regardless of data collection
mode [5]. Based on current recommendations [20, 21], using
mixed modes in a clinical trial would require a quantitative
measurement equivalence study if there are more than
minimal differences in the presentation of the PRO instru-
ment on the different modes (e.g., smartphone screen vs the
large monitor of a desktop PC). This approach becomes
impractical in the BYOD model where the number of
potential devices, operating systems, and browsers available
could be extensive. However,with appropriate programming
across the various operating systems and browsers, the only
material difference becomes the size of the screen (and font)
on the device the subject is using to enter data. In this case, an
assessment of the measurement equivalence of the smallest
screen size to the largest screen that would realistically be
available for each operating system should be sufficient. As
mentioned previously in regard to ePRO more generally, an
accumulation of evidence fromBYOD-based studiesmay, at
some point in the future, support the assumption of mea-
surement equivalence across screen-based devices in most
circumstances where a faithful migration has been rendered.
6.3 Paying for Data
During traditional ePRO studies where clinical trial sub-
jects are provided hardware by the trial sponsor, data
transmission costs (e.g., submitting data from a daily diary
completed on a smartphone) are automatically covered by
the sponsor with the included SIM card on the device.
However, in the BYOD model, the expectation is that the
subject is using his or her own device and, as a result, will
incur data transmission costs as part of, or in addition to,
the subjects’ cellular plan. The subject should have a rea-
sonable expectation of being reimbursed for these costs in
addition to any other compensation received for partici-
pating in the study.
6.4 People Without Access to a Suitable Device
The underlying assumption of the BYOD model is that
study subjects have their own device, which they can, in
fact, bring. In FDA parlance, the subjects are required to
provide a device that is ‘fit for purpose.’ However, even
high global Internet and mobile phone penetration does not
guarantee that the patient population for a particular study
will all have a suitable device that can access the study
measures, and there is little reason to believe that smart-
phone penetration will ever reach 100 %. For example, in
the US *45 % of all adults own smartphones, but own-
ership varies widely based on age, income, education, and
geographic location. However, Blacks (47 %) and His-
panics (49 %), who are traditionally underrepresented in
clinical trials in the US, had higher rates of smartphone
ownership than non-Hispanic whites (42 %) [26].
There are two potential approaches to addressing the
device access issue:
– Require ownership of an appropriate device in the
inclusion criteria. This would help to ensure that
participants in the study have an appropriate device on
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which to enter data. However, this approach raises
serious concerns about selection bias within the sample.
Potentially, this could lead to exclusion of important
segments of the target population from the clinical trial.
– Provide participants who do not have appropriate
devices with stand-alone hardware, while allowing
those with an appropriate device to follow the BYOD
model. This approach would avoid issues around
excluding certain segments of the target population,
but attenuates one of the key perceived strengths of the
BYOD model (i.e., avoiding costs associated with
providing devices).
Whether selection bias is a problem will depend on the
size of the target patient population. If the target population
is hard to find, then the idea of providing devices would be
attractive as it will allow those that have the right device to
use their own, but it would not exclude those that do not. If
the target population is easy to attain, then the ownership of
the correct device can be used as an inclusion criterion.
6.5 Security, Both Physical and Electronic
When evaluating BYOD solutions, ensuring protection of
the subject’s private information and the data being col-
lected should be a paramount concern.
Box 2 provides examples of questions that should be
considered when evaluating any BYOD system. The
answers to these questions and others like them will impact
the level of confidence with BYOD in general and specific
solutions in particular.
Smartphones and tablets present problems when lost or
stolen. The physical security can be breached with a brute
force attack, so extra design precautions need to be taken to
ensure that the patient’s privacy and anonymity are pro-
tected. There are also additional security considerations
that need to be addressed to make sure that authentication
controls are not bypassed. Such privacy and authentication
controls are part of a ‘normal’ ePRO build, no matter what
modality is being used, and apply to all aspects of a per-
son’s digital life, not just his or her health-related data.
6.6 Ownership
In BYOD studies, the sponsor no longer owns and con-
trols the device in the same way as if the device were
deployed to the subjects. It should be recognized that
these are multi-purpose devices that cannot be locked
down in a way that disables any of the other device’s
functions during data collection. In addition to completing
the study protocol activities (i.e., responding to the PRO
instrument at the appropriate time) on their devices, study
subjects will be making calls, sending text messages,
playing games, surfing the Internet, and interacting with
friends on social media sites on this same device. These
are ‘environmental risks’ of collecting data in an unsu-
pervised setting and can cause data collection to be
interrupted or delayed. However, this issue is not unique
to BYOD studies; clinical trial sponsors have never been
able to control a subject’s behavior when they are com-
pleting any PRO assessment remotely, be it on paper or
any other data collection mode.
Storage, or the amount of space available on the device,
also becomes an issue with devices that are not under the
sponsor’s control. This is especially true when considering
all the tasks for which the subject uses his or her mobile
device (e.g., watching videos, taking pictures, playing
music, and downloading other apps). In addition, the sub-
ject can delete the app at any time, even with captured and
un-submitted data. However, as part of the inclusion cri-
teria, potential subjects could be required to agree to not
delete the study app. Some checks can be conducted by site
staff and via online monitoring; however, these options are
limited.
Compliance questions are also raised since the sponsor
does not own the device and can’t force the subject to have
Box 2: Example security quesons to ask when evaluang BYOD soluons
Are the data stored on the device for any amount of me? If so, are the data encrypted 
at rest?
How are the data transferred from the device and where does it go? Are the data stored 
on a server or in the Cloud?
What security measures are in place to protect the data in transit? 
What detecon measures are in place to detect a security breach?
Can data be removed from the device automacally aer it has been successfully 
received in my clinical data storage system?
How do you ensure that only the study subject can send data?
Do you have a remote capability to wipe or shut down a lost or stolen device?
What steps have you taken to protect the subject’s privacy?
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notifications turned on. If the subject chooses to turn off
notifications, these automated alerts to complete required
data entry task do not work. Like the agreement to not
delete the app as part of the inclusion criteria, subjects
could be required not to turn off notifications, which are
associated with high compliance [27, 28]. If the subject
does turn off notifications during the trial and compliance
with data entry is negatively impacted, the study staff’s
review of online reports should alert them to a compliance
problem.
6.7 Technology Changes
The set of mobile operating systems that support the
mobile market are changing constantly and quickly. For
sponsors of clinical trials, the pace with which change
happens will become a major challenge. Agile software
developers iterate through releases quickly, with some
deploying new features on a monthly basis. Support for the
previous version of the software is dropped as soon as the
new app is made available because app stores only allow
one version of the software to be sold at any time. Increases
in the amount of infrastructure necessary to support the
complex functionality of existing solutions and increased
maintenance cycle costs for vendors may drive prices
upward. The result may be that the cost-benefit ratio of
switching to a BYOD solution is not as large as anticipated.
7 Discussion and Conclusions
The movement toward ePRO data collection has been one
of the most significant advances in PRO measurement.
Based on important advances in technology and in the
infrastructure to enable the effective deployment of the
technology, ePRO is quickly becoming the gold standard
for PRO data capture in clinical trials. There is no doubt
that electronic capture of PRO endpoint data is here to stay.
Its numerous advantages over paper-based data collection
result in more complete and accurate PRO datasets, which
could be the difference between a failed and successful
clinical trial. The significance of this has not been lost on
the regulatory and scientific community. The FDA has
asserted its support and expectations for electronic capture
of clinical trial source data, including PRO endpoints [5,
19]. ISPOR has established three task forces that have
issued ePRO-related good research practice recommenda-
tions [20, 21, 23]. In addition, due to the increasing
importance of ePRO data collection in clinical trials, rep-
resentatives of the pharmaceutical firms in the PRO Con-
sortium (http://www.c-path.org/programs/pro) and ePRO
system providers in the ePRO Consortium are working
collaboratively on the development and implementation of
ePRO data collection systems for all new PRO instruments
being developed within the PRO Consortium. The future of
ePRO data collection in clinical trials is bright and,
although there remain a number of issues to be resolved,
the promise of BYOD opens a new chapter in its evolution.
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